10.1038/nature12111 66 HuangW.WangY.TianW.CuiX.TuP.LiJ.et al (2022)
How Endogenous Hormone Release Differs from Synthetic GLP-1 Drugs The study centers on a difference between endogenous GLP-1 stimulation, the bodys own secretion of glucagon-like peptide-1 from intestinal cells, and prescription receptor agonists
Nonetheless, whether the specific mechanism of this is related to the transdifferentiation of VSMCs to a bone-like phenotype, loss in SMC lineage markers, enhanced pro-calcific microRNAs, increased intracellular calcium level, apoptosis, or aberrant DNA damage response (DDR) requires further investigation
Lilly said earlier this year it would reduce the cost of initial doses of Zepbound to $349
GLP-1 (glucagon-like peptide-1) suppresses appetite and slows digestion, so you feel full longer after eating
Machine learning identifies the independent role of dysplasia in the prediction of response to chemotherapy in AML